FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody or an antigen-binding fragment thereof specifically binding to the human interleukin-4 receptor α(hIL-4Rα), the method for production thereof, and to a composition and set containing the antibody. Also disclosed is an isolated nucleic acid molecule encoding the above antibody or the antigen-binding fragment thereof, as well as a vector and a host cell containing the molecule.
EFFECT: invention provides a possibility to effectively prevent or treat a disease or disorder associated with IL-4/IL-4Rα signalling in the human body.
15 cl, 4 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| METHODS FOR INCREASING VACCINE EFFICIENCY BY INJECTING IL-4R ANTAGONIST | 2017 |
|
RU2753869C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| ANTIBODY FOR SPECIFIC BINDING WITH INTERLEUKIN 4 RECEPTOR | 2017 |
|
RU2774446C2 |
| HUMANIZED SINGLE-DOMAIN ANTIBODY TO IL-4Rα AND ITS USE | 2021 |
|
RU2816867C1 |
| METHODS FOR TREATMENT OF ACTIVE EOSINOPHILIC ESOPHAGITIS | 2018 |
|
RU2776651C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
